The data showed that RGL2 upregulation significantly (p < 0.05) correlated with an increased hazard ratio in the enrolled CRC cohorts, as well as two cohorts with blood and breast cancer (Figure 2A). The gene discussed is RGL2; the disease is breast cancer.